ABL1 is an inclusion eligibility criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain AFF1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ASXL1 is altered in 11.27% of therapy-related myelodysplastic syndrome patients [2].

ASXL1 is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain ASXL1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) [3].

BCOR is altered in 2.82% of therapy-related myelodysplastic syndrome patients [2].

BCOR is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is an inclusion eligibility criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain BCR status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CBFB status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

CBL is altered in 2.82% of therapy-related myelodysplastic syndrome patients [2].

CBL is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CBL status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

DEK is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain DEK status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

DNMT3A is altered in 16.9% of therapy-related myelodysplastic syndrome patients [2].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

ELL is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain ELL status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

EZH2 is altered in 4.23% of therapy-related myelodysplastic syndrome patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain FLT3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IGH status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 1.41% of therapy-related myelodysplastic syndrome patients [2].

KIT is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain KIT status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

KMT2A is altered in 2.0% of therapy-related myelodysplastic syndrome patients [2].

KMT2A is an inclusion eligibility criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain KMT2A status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

KRAS is altered in 2.82% of therapy-related myelodysplastic syndrome patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

MAF is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MAF status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 6 clinical trials for therapy-related myelodysplastic syndrome, of which 6 are open and 0 are closed. Of the trials that contain MECOM status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].

MLF1 is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain MLF1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain MLLT1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain MLLT10 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain MLLT3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain MLLT4 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain NPM1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

NRAS is altered in 2.82% of therapy-related myelodysplastic syndrome patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain NRIP3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain NUP214 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain PBX1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PHF6 is altered in 2.82% of therapy-related myelodysplastic syndrome patients [2].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

RIT1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 6 clinical trials for therapy-related myelodysplastic syndrome, of which 6 are open and 0 are closed. Of the trials that contain RPN1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].

RUNX1 is altered in 5.63% of therapy-related myelodysplastic syndrome patients [2].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain RUNX1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains RUNX1T1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

SF3B1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

SRSF2 is altered in 4.23% of therapy-related myelodysplastic syndrome patients [2].

SRSF2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is altered in 4.0% of therapy-related myelodysplastic syndrome patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain TCF3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

TET2 is altered in 11.27% of therapy-related myelodysplastic syndrome patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 42.25% of therapy-related myelodysplastic syndrome patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

U2AF1 is altered in 2.82% of therapy-related myelodysplastic syndrome patients [2].

U2AF1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains U2AF1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

ZRSR2 is altered in 8.45% of therapy-related myelodysplastic syndrome patients [2].

ZRSR2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ZRSR2 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].